Crossmark

Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate

Crossref DOI link: https://doi.org/10.1186/s12933-018-0778-9

Published Online: 2018-10-22

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sardu, Celestino http://orcid.org/0000-0001-5099-3790
Paolisso, Pasquale

Sacra, Cosimo

Santamaria, Matteo

de Lucia, Claudio

Ruocco, Antonio

Mauro, Ciro

Paolisso, Giuseppe

Rizzo, Maria Rosaria

Barbieri, Michelangela

Marfella, Raffaele
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03282136 at ClinicalTrials.gov

Documents that mention this clinical trial

Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate
https://doi.org/10.1186/s12933-018-0778-9
License Information

Text and Data Mining valid from 2018-10-22

Version of Record valid from 2018-10-22
More Information

Article History

Received: 10 August 2018

Accepted: 10 October 2018

First Online: 22 October 2018

Document is current

Any future updates will be listed below